Does the IL-6/KL-6 ratio distinguish different phenotypes in COVID-19 Acute Respiratory Distress Syndrome? An observational study stemmed from prospectively derived clinical, biological, and computed tomographic data.

Date publication

mai 2025

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas , Dr CHAMARAUX-TRAN Thiên-Nga

Tous les auteurs :
Partouche N, Maumy M, Chamaraux-Tran TN, Bertrand F, Schneider F, Meyer N, Solis M, Fafi-Kremer S, Noll E, Pottecher J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40397955

Résumé

As new SARS-CoV-2 variants emerge and as treatment of COVID-19 ARDS remains exclusively supportive, there is an unmet need to better characterize its different phenotypes to tailor personalized treatments. Clinical, biological, spirometric and CT data hardly allow deciphering of Heavy (H), Intermediate (I) and Light (L) phenotypes of COVID-19 ARDS and the implementation of tailored specific strategies (prone positioning, PEEP settings, recruitment maneuvers). We hypothesized that the ratio of two pivotal COVID-19 biomarkers (interleukin 6 [IL-6] and Krebs von den Lungen 6 [KL-6], related to inflammation and pneumocyte repair, respectively) would provide a biologic insight into the disease timeline allowing 1) to differentiate H, I and L phenotypes, 2) to predict outcome and 3) to reflect some of CT findings.

Mots clés

Humans, COVID-19, complications, Interleukin-6, blood, Male, Middle Aged, Female, Respiratory Distress Syndrome, blood, Tomography, X-Ray Computed, Phenotype, Biomarkers, blood, SARS-CoV-2, Aged, Mucin-1, blood, Retrospective Studies, Prospective Studies, Adult

Référence

PLoS One. 2025 05 21;20(5):e0321533